MedTrace Logo

Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

NCT00100165 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2020-01-29

Study results available
· View outcomes & findings →

Summary

The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally administered nicotinic cholinergic agonist, will improve attention and other neuropsychological dysfunctions in schizophrenia, leading to improved psychosocial outcome.

Conditions

Interventions

DRUG

Placebo

Placebo by mouth twice a day for 4 weeks

DRUG

3-(2,4 dimethoxybenzylidene anabaseine) 150 mg

3-(2,4 dimethoxybenzylidene) 150 mg by mouth twice a day for 4 weeks

DRUG

3-(2,4 dimethoxybenzylidene anabaseine) 75 mg

3-(2,4 dimethoxybenzylidene) 75 mg by mouth twice a day for 4 weeks

Sponsors & Collaborators

  • VA Office of Research and Development

    collaborator FED

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Robert Freedman, MD · VA Eastern Colorado Health Care System, Denver, CO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00100165 on ClinicalTrials.gov